The multicenter, randomized, double blind, placebo-controlled study will enroll 70 patients with moderate to severe nasal polyposis with and without asthma at sites in both the U.S. and Europe. For more information, please visit www.clinicaltrials.gov (NCT02734849).
About Nasal Polyposis
Nasal polyposis is a disease characterized by the growth of polyps in the nasal cavities. In the majority of patients, these polyps are highly enriched for mast cells and eosinophils. Patients with nasal polyposis have blocked nasal passages and sinuses with obstructed breathing and impaired sense of taste and smell that can result in a significant impact on quality of life. These patients are also prone to recurrent nasal infections and asthma, which can be severe in nature. Nasal polyposis is difficult to control with current treatment options, which include topical steroids and surgery.
AK001 is a therapeutic antibody that selectively targets mast cells and eosinophils. Binding of AK001 to specific receptors present on mast cells and eosinophils results in the inhibition of mast-cell inflammatory signaling and the removal of tissue-based eosinophils. The direct effect of AK001 on mast cells and eosinophils bypasses the redundancy of cytokine signaling pathways without directly affecting other cells of the immune system. AK001 has the potential to be of benefit in a wide spectrum of severe inflammatory and allergic diseases. Allakos has demonstrated activity of AK001 in multiple pre-clinical models and completed a Phase I clinical trial with AK001 in healthy volunteers in which it was well tolerated and demonstrated pharmacodynamic activity.
Allakos is a privately held clinical-stage company developing a pipeline of novel therapeutics that selectively target mast cells and eosinophils; important immune effector cells that are involved in a broad spectrum of inflammatory and allergic conditions as well as several rare proliferative diseases with high unmet need. The company's lead drug candidates AK001 and AK002 use novel approaches to target mast cells and eosinophils and are in clinical development for the treatment of severe inflammatory diseases and other diseases characterized by excess activity of mast cells and eosinophils. Allakos is located in San Carlos, California.
For further information, visit www.Allakos.com.
Chief Business Officer
T: 650 597 5002
Matt Middleman, M.D.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allakos-initiates-phase-2-trial-of-ak001-in-patients-with-nasal-polyposis-300324298.html
SOURCE Allakos, Inc.